Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
US-2024199583-A1 · Jun 20, 2024 · US
Aryl compound and making method
US9840484B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9840484-B2 |
| Application number | US-201715398838-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 5, 2017 |
| Priority date | Jan 7, 2016 |
| Publication date | Dec 12, 2017 |
| Grant date | Dec 12, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An aryl compound terminated with at least three glycidyl groups and at least three (meth)allyl groups, having formula (1) wherein R 1 is a C 3 -C 20 hydrocarbon, R 2 is hydrogen or methyl, and n is 3 or 4 is novel. It is prepared by reacting an aryl compound having at least three (meth)allyl-containing phenol groups with a 2-halomethyloxirane.
First claim
Opening claim text (preview).
The invention claimed is: 1. An aryl compound terminated with glycidyl and (meth)allyl groups, having the general formula (1): wherein R 1 is a trivalent or tetravalent C 3 -C 20 hydrocarbon group, R 2 is hydrogen or methyl, and n is 3 or 4. 2. The aryl compound of claim 1 wherein R 1 in formula (1) is a trivalent or tetravalent C 3 -C 15 hydrocarbon group. 3. The aryl compound of claim 2 wherein R 1 has at least an aromatic or alicyclic group. 4. The aryl compound of claim 3 wherein R 1 is selected from the following groups: wherein the wavy line designates a valence bond. 5. A method for preparing an aryl compound having glycidyl and (meth)allyl groups, represented by the general formula (1) : wherein R 1 is a trivalent or tetravalent C 3 -C 20 hydrocarbon group, R 2 is hydrogen or methyl, and n is 3 or 4, the method comprising the step of reacting an aryl compound having (meth)allyl-containing phenol groups, represented by the general formula (2): wherein R 1 is a trivalent or tetravalent C 3 -C 20 hydrocarbon group, R 2 is hydrogen or methyl, and n is 3 or 4, with a 2-halomethyloxirane having the general formula (3): wherein X is halogen.
Assignees
Inventors
Classifications
- C07D407/14Primary
containing three or more hetero rings · CPC title
- C07D303/30Primary
Ethers of oxirane-containing polyhydroxy compounds in which all hydroxyl radicals are etherified with oxirane-containing hydroxy compounds · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9840484B2 cover?
- An aryl compound terminated with at least three glycidyl groups and at least three (meth)allyl groups, having formula (1) wherein R 1 is a C 3 -C 20 hydrocarbon, R 2 is hydrogen or methyl, and n is 3 or 4 is novel. It is prepared by reacting an aryl compound having at least three (meth)allyl-containing phenol groups with a 2-halomethyloxirane.
- Who is the assignee on this patent?
- Shinetsu Chemical Co
- What technology area does this patent fall under?
- Primary CPC classification C07D407/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).